Key facts
- This page summarizes Daniel Tardiff's Form 4 filing for Camp4 Therapeutics Corp (CAMP).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 19 Aug 2026, 20:46.
Daniel Tardiff - 19 Aug 2026 Form 4 Insider Report for Camp4 Therapeutics Corp (CAMP)
- Reporting relationship
- Chief Scientific Officer
- Issuer ticker
- CAMP
- Reported as of
- 19 Aug 2026
- Net transaction value
- -$8,273
- SEC form
- 4
- Accepted by SEC
- 19 Aug 2026, 20:46:05 UTC
- Prior SEC filing
- 03 Apr 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Daniel Tardiff
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Daniel Tardiff filed Form 4 for Camp4 Therapeutics Corp (CAMP) on 19 Aug 2026.
Change
- Previous filing in this sequence was filed on 03 Apr 2026.
- Current net transaction value: -$8,273.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0002089301
Primary reporting owner
Tardiff Daniel
- Relationship
- Chief Scientific Officer
- Address
- C/O CAMP4 THERAPEUTICS CORPORATION, 100 TALCOTT AVENUE, SUITE 201, WATERTOWN
- Signature
- /s/ Daniel Tardiff
- Signature date
- 19 Aug 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CAMP
transaction
Common Stock
Sale
- Transaction value
- $8,273
- Shares
- -1,738
- Change %
- -100%
- Price
- $4.76
- Shares after
- 0
- Date
- 19 Aug 2026
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The shares sold were previously acquired by the reporting person pursuant to the CAMP4 Therapeutics Corporation Employee Stock Purchase Plan (the "ESPP") for the purchase period of January 1, 2026 through June 30, 2026 in a transaction that was exempt under Rule 16b-3(c).